Evidence map›Paper›PMID 32185490›Full record

ArticleEuropean archives of psychiatry and clinical neuroscience2020

Cannabis use influence on peripheral brain-derived neurotrophic factor levels in antipsychotic-naïve first-episode psychosis.

A Toll, D Bergé, K Burling, L Scoriels, D Treen, C Monserrat, F Marmol, X Duran, P B Jones, V Pérez-Solà and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of psychiatry and clinical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

A TollInstitut de Neuropsiquiatria I Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain.
D BergéInstitut de Neuropsiquiatria I Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain.
K BurlingLab Cambridge Core Biochemical Assay Laboratory, Clinical Biochemistry, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.
L ScorielsDepartment of Psychiatry and Behavioral and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
D TreenDepartment of Psychiatry, Hospital Germanes Hospitalaries Sagrat Cor, Martorell, Spain.
C MonserratInstitut de Neuropsiquiatria I Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain.
F MarmolPharmacology Unit, Department of Medicine, Barcelona University, Barcelona, Spain.
X DuranFundació Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
P B JonesDepartment of Psychiatry and Behavioral and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
V Pérez-SolàInstitut de Neuropsiquiatria I Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain.
E Fernandez-EgeaDepartment of Psychiatry and Behavioral and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
A ManéInstitut de Neuropsiquiatria I Adiccions (INAD), Parc de Salut Mar, Barcelona, Spain. manesantacana@yahoo.es.
University of Cambridge · GBCentro de Investigación Biomédica en Red de Salud Mental · ESMunicipal Institute for Medical Research · ESCambridge University Hospitals NHS Foundation Trust · GBHospital del Mar Research Institute · ESHospital Mare de Déu de la Mercè · ESParc de Salut · ESUniversitat de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study is to determine whether cannabis influences BDNF levels in patients with psychosis (FEP) and healthy volunteers (HV) to help understand the role of BDNF in psychosis. We assessed the association between BDNF and cannabis in a cohort of FEP antipsychotic-naïve patients and HV, whilst controlling for other potential confounding factors. 70 FEP drug-naive patients and 57 HV were recruited. A sociodemographic variable collection, structured clinical interview, weight and height measurement, substance use determination, and blood collection to determine BDNF levels by ELISA analysis were done. In FEP patients, cannabis use was associated with BDNF levels (high cannabis use was associated with lower BDNF levels). Moreover, cannabis use was statistically significantly associated with age (high use of cannabis was associated with younger age). In HV, no relationship between cannabis use and BDNF levels was observed. Otherwise, cannabis use was significantly associated with tobacco use, so that high cannabis users were also high tobacco users. This study showed a different association between cannabis use and BDNF levels in FEP patients compared with HV, particularly, with high doses of cannabis. These findings may help understand the deleterious effects of cannabis in some vulnerable individuals, as well as discrepancies in the literature.

Indexed as

AdultAge FactorsBrain-Derived Neurotrophic FactorCohort StudiesFemaleHumansMaleMarijuana UsePsychotic DisordersYoung AdultBDNF protein, humanBrain-Derived Neurotrophic FactorBiomarkersBNDFCannabisPsychosisSchizophrenia

Identifiers

PMID32185490
OpenAlexW3011879373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.